8-K: BioAffinity Faces Nasdaq Delisting Amid Sales Surge

BioAffinity Technologies received a Nasdaq delisting notice due to non-compliance with minimum bid price and equity requirements, while simultaneously reporting a significant surge in CyPath Lung test sales.

Summary

• Received written notice from Nasdaq on August 7, 2025, indicating failure to regain compliance with the Minimum Bid Price Requirement ($1.00 per share) by the August 6, 2025 deadline.
• Not eligible for a second 180-day compliance period due to non-compliance with the minimum stockholders' equity requirement for initial listing on the Nasdaq Capital Market.
• Stockholders' equity was $1,439,404 as of March 31, 2025, below Nasdaq's $2,500,000 minimum requirement.
• Unless an appeal is submitted by August 14, 2025, securities will be scheduled for delisting and suspension from Nasdaq on August 18, 2025.
• The company intends to submit an appeal to Nasdaq on August 14, 2025, which will stay the delisting pending a Panel decision.
• Reported accelerating growth in commercial sales of CyPath Lung, a noninvasive diagnostic for early-stage lung cancer.
• Completed CyPath Lung tests in July represent a 72% increase over the previous monthly average for the first six months of 2025.
• Achieved back-to-back record monthly sales in June and July.
• Reaffirmed a forecast of 3X year-over-year revenues for CyPath Lung.

Sentiment

Score: 4

Explanation: While the company reports strong commercial sales growth for its flagship product, the immediate threat of Nasdaq delisting due to non-compliance with listing rules presents a significant negative overhang and uncertainty for investors.

Positives

• Commercial sales of CyPath Lung surged, with July test volume increasing 72% over the prior monthly average for the first six months of 2025.
• Achieved back-to-back record monthly sales in June and July, indicating strong market momentum.
• Reaffirmed a forecast of 3X year-over-year revenues for CyPath Lung, signaling robust future growth expectations.
• CyPath Lung demonstrated high efficacy in detecting Stage 1A lung cancer in recent case studies, even when standard imaging and risk models indicated benign nodules.
• Clinical study results showed CyPath Lung had 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules.
• Successful pilot marketing program in Texas has demonstrated an effective approach to the medical community.
• Prepared to meet increased demand and plans for expansion into additional key markets, including the Mid-Atlantic region and the Veterans Administration healthcare system.

Negatives

• Received a Nasdaq delisting notice for failing to regain compliance with the Minimum Bid Price Requirement ($1.00 per share) by the August 6, 2025 deadline.
• Not eligible for a second 180-day compliance period due to non-compliance with the minimum stockholders' equity requirement for initial listing on the Nasdaq Capital Market.
• Stockholders' equity of $1,439,404 as of March 31, 2025, is below Nasdaq's minimum requirement of $2,500,000.
• Securities are scheduled for delisting from The Nasdaq Capital Market and suspension at the opening of business on August 18, 2025, unless an appeal is filed by August 14, 2025.
• The equity deficiency now serves as an additional basis for delisting.
• There is no assurance that the company will be able to evidence compliance with Nasdaq listing rules prior to the hearing or that an extension period will be granted.

Risks

• Potential delisting of common stock and warrants from The Nasdaq Capital Market if the appeal to the Nasdaq Panel is unsuccessful or if compliance is not regained.
• Inability to regain compliance with the Nasdaq Minimum Bid Price Requirement ($1.00 per share).
• Inability to regain compliance with the Nasdaq Continued Listing Equity Requirement ($2,500,000 minimum stockholders' equity).
• The Nasdaq Panel may not grant an extension period to regain compliance, or if granted, the company may not regain compliance within that period.
• Forward-looking statements regarding the timing of the hearing and the Panel's decision are subject to risks and uncertainties, and actual timelines may be shorter than expected, which could be unfavorable.
• Reliance on the successful implementation of market expansion strategies and continued adoption of CyPath Lung by clinicians and payers.

Future Outlook

The company intends to appeal Nasdaq's delisting determination by August 14, 2025, which will stay the delisting pending a decision from a Nasdaq hearings panel. At the hearing, the company plans to present its views and plans to regain compliance with both the Minimum Bid Price Requirement and the Continued Listing Equity Requirement. The company also plans to expand its market presence for CyPath Lung into additional key markets, including the Mid-Atlantic region and the Veterans Administration healthcare system, building on the success of its pilot marketing program in Texas.

Management Comments

• "CyPath Lungs ability to detect lung cancer at its earliest stage, as evidenced by recent case studies, has fueled the growing adoption of CyPath Lung across a growing base of clinicians, which is driving momentum in the marketplace." Maria Zannes, President and CEO.
• "This early Q3 surge is especially encouraging because it reflects increasing awareness and trust in our technologys ability to support earlier, more accurate diagnosis of lung cancer, especially for high-risk patients with indeterminate lung nodules." Maria Zannes, President and CEO.
• "Physician demand, payer coverage, and patient access continue to build a strong foundation for long-term revenue growth." J. Michael Edwards, Chief Financial Officer.
• "The success of our pilot marketing program in Texas, which has approximately 6% of the total number of U.S. pulmonologists, has demonstrated that our approach to the medical community is sound and effective. We are prepared to meet increased demand as we implement our strategy to enter additional key markets, including our expansion in the Mid-Atlantic region and the Veterans Administration healthcare system." J. Michael Edwards, Chief Financial Officer.
• "The key to improving survival rates for lung cancer is early detection. When lung cancer is found at Stage 1A, there are many curative options." Gordon Downie, MD, PhD, Chief Medical Officer.
• "Physicians are finding that a CyPath Lung test result – whether it is positive or negative for cancer – can better inform shared decision making between doctor and patient and ease anxiety about appropriate next steps." Gordon Downie, MD, PhD, Chief Medical Officer.

Industry Context

The announcement highlights the growing demand for noninvasive diagnostics in early cancer detection, particularly for lung cancer, where early diagnosis significantly improves survival rates. BioAffinity Technologies' CyPath Lung, leveraging flow cytometry and AI, positions the company within the rapidly evolving precision medicine and diagnostic sector. The focus on high-risk patients with indeterminate lung nodules addresses a critical unmet need in the diagnostic pathway, aiming to provide clarity where traditional imaging and risk models are inconclusive. The company's expansion strategy into key U.S. markets and the Veterans Administration healthcare system reflects a broader trend of diagnostic companies seeking to integrate their technologies into established clinical workflows and large healthcare systems.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparison. However, CyPath Lung's reported 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (<20mm) are strong metrics for a noninvasive diagnostic in this field, where early detection is paramount for improving patient outcomes.

Stakeholder Impact

• Shareholders face significant risk of delisting from Nasdaq, which could lead to reduced liquidity and potential loss of investment value.
• Employees may experience uncertainty regarding the company's future listing status and its implications for the business.
• Customers and patients may benefit from the continued commercial availability and expansion of CyPath Lung, a noninvasive diagnostic for early-stage lung cancer.
• Creditors may face increased risk due to the company's non-compliance with Nasdaq listing standards and low stockholders' equity.

Next Steps

• Submit an appeal to the Nasdaq hearings panel by August 14, 2025, to stay the delisting and suspension of securities.
• Present views and plans to regain compliance with Nasdaq's Minimum Bid Price Requirement and Continued Listing Equity Requirement at the hearing.
• Await the Nasdaq Panel's decision, typically within 30 days after the hearing.
• Implement strategy to enter additional key markets, including expansion in the Mid-Atlantic region and the Veterans Administration healthcare system, to meet increased demand for CyPath Lung.

Key Dates

Recommendation

The company faces an imminent delisting threat from Nasdaq, which introduces substantial risk and uncertainty. However, the reported accelerating sales growth for CyPath Lung and its demonstrated efficacy in early cancer detection represent a strong underlying business positive. An investor might hold to observe the outcome of the Nasdaq appeal and the company's ability to regain compliance, weighing the significant delisting risk against the promising product performance.

Keywords

bioAffinity Technologies, BIAF, CyPath Lung, lung cancer, diagnostics, noninvasive, Nasdaq, delisting, biotechnology, early cancer detection, SEC filing, 8-K, medical device, cancer screening